Evidence map›Paper›PMID 40763716›Full record

ArticleFetal diagnosis and therapy2026

Screening for Term Preeclampsia at 35 to 37 Weeks of Gestation: A Single-Center Experience.

Selina Manuela Diethelm, Thabea Musik, Cécile Monod, Lysann Hildebrandt, Olav Lapaire, Gwendolin Manegold-Brauer, Sofia Amylidi-Mohr, Beatrice Mosimann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fetal diagnosis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Selina Manuela DiethelmFaculty of Medicine, University of Basel, Basel, Switzerland.
Thabea MusikDepartment of Obstetrics and Gynaecology, University Hospital of Basel, University of Basel, Basel, Switzerland.
Cécile MonodDepartment of Obstetrics and Gynaecology, University Hospital of Basel, University of Basel, Basel, Switzerland.
Lysann HildebrandtDepartment of Obstetrics and Gynaecology, University Hospital of Basel, University of Basel, Basel, Switzerland.
Olav LapaireDepartment of Obstetrics and Gynaecology, University Hospital of Basel, University of Basel, Basel, Switzerland.
Gwendolin Manegold-BrauerDepartment of Obstetrics and Gynaecology, University Hospital of Basel, University of Basel, Basel, Switzerland.
Sofia Amylidi-MohrDepartment of Obstetrics and Gynaecology, University Hospital of Basel, University of Basel, Basel, Switzerland.
Beatrice MosimannDepartment of Obstetrics and Gynaecology, University Hospital of Basel, University of Basel, Basel, Switzerland, beatrice.mosimann@usb.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Introduction: Prevention of preeclampsia has short- and long-term benefits for maternal health. Recent data suggest that combined screening at 35-37 weeks of gestation with anamnestic risk factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), and angiogenic profile (sFlt-1/PlGF) detects up to 80% of all tPE. The aim of this retrospective analysis was to test the performance of third-trimester screening for tPE in a single center in Switzerland.

methodsSingleton pregnancies with complete background risk assessments, MAP, and, if available, UtA-PI and sFlt-1/PlGF from 2018 to 2023 were included and risks were calculated on the FMF London website.

results1,121 pregnancies, including 22 (2.0%) with tPE, were analyzed. Median MAP-MoM [IQR] in tPE was 1.08 [1.00-1.14], compared to 0.98 [0.92-1.04] in controls (p < 0.0001). Median UtA-PI-MoM [IQR] in tPE was 1.04 [0.85-1.27] versus 0.99 [0.82-1.15] (p = 0.56). No sFlt-1/PlGF recordings in tPE were available for analysis. The detection rate in combined screening was 15/22 (68.2%) compared to screening by anamnestic risk factors only of 9/22 (40.9%).

conclusionThis analysis shows that combined screening at 35-37 weeks of gestation including anamnestic risk factors and MAP performs better than screening by anamnestic risk factors alone. These results should further be verified in a prospective trial including all markers. </p>.

Indexed as

Pre-EclampsiaAdultBiomarkersFemaleGestational AgeHumansPlacenta Growth FactorPregnancyPregnancy Trimester, ThirdPulsatile FlowRetrospective StudiesUltrasonography, PrenatalUterine ArteryVascular Endothelial Growth Factor Receptor-1BiomarkersFLT1 protein, humanPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1PreeclampsiaScreeningThird trimester

Identifiers

PMID40763716
PMCPMC12503657

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.